Results 231 to 240 of about 453,156 (401)

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source

Posterior Reversible Encephalopathy Syndrome:  Two Cases of a Rare Complication of Hypertensive Disorders in Pregnancy [PDF]

Natasha Fonseka, M. Karunarathne
openalex   +1 more source

Toxic Encephalopathy [PDF]

Journal of General Internal Medicine, 2012
Abhishek, Agarwal, Tobias, Vancil
openaire   +2 more sources

Commentary: Newly diagnosed hepatic encephalopathy presenting as non-convulsive status epilepticus: a case report and literature review. [PDF]

Front Neurol
Gélisse P, Crespel A.
europepmc   +1 more source

Detection of Microhemorrhage in Posterior Reversible Encephalopathy Syndrome Using Susceptibility-Weighted Imaging

, 2012
Alexander M. McKinney, Başar Sarıkaya, C. Gustafson, C. L. Truwit   +3 more
openalex   +1 more source

Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency

Epilepsia, EarlyView.
Abstract Objective GRIN‐related disorders due to pathogenic variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes are associated with altered N‐methyl‐D‐aspartate receptor (NMDAR) function. Functional changes include gain (GoF) and loss of receptor function (LoF). Clinical reports describing the use of the NMDAR blocker memantine in GRIN‐related disorders
Maike Karnstedt, Riley E. Perszyk, Scott J. Myers, Ellington McDaniels, Marta Somorai, Ingo Borggraefe, Danielle C. M. Veenma, An‐Sofie Schoonjans, Pasquale Striano, Tadeu A. Fantaneanu, Steffen Syrbe, Kristen Park, Wenjuan Chen, Hongjie Yuan, Stephen F. Traynelis, Timothy A. Benke, Johannes R. Lemke, Ilona Krey   +17 more
wiley   +1 more source

Economic and epidemiological burden of medical complications of unregulated drug use among people who inject drugs in Québec. [PDF]

Subst Abuse Treat Prev Policy
Lim J, Panagiotoglou D.
europepmc   +1 more source

Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study

Epilepsia, EarlyView.
Abstract Objective CDKL5 deficiency disorder (CDD) is a rare X‐linked developmental and epileptic encephalopathy caused by loss‐of‐function variants in the CDKL5 gene. Preclinical experiments using enzyme replacement or gene therapies show promise and could be transformative therapies.
Xavier Liogier d'Ardhuy, CANDID Partners, Tricia Cimms, Kristina Lindsten, Marco Rizzo, Alison Skrinar, Peter St. Wecker, Ana Mingorance, Orrin Devinsky   +8 more
wiley   +1 more source

Magnetic resonance imaging scanning susceptibility weighted imaging sequences in the diagnosis and prognostic evaluation of neonatal hypoxic-ischemic encephalopathy

Hui Zhao, Haitao Wang
openalex   +1 more source

Moderate hypothermia to treat perinatal asphyxial encephalopathy.

New England Journal of Medicine, 2009
D. Azzopardi, B. Strohm, A. Edwards, L. Dyet, H. Halliday, E. Juszczak, O. Kapellou, M. Levene, N. Marlow, E. Porter, M. Thoresen, A. Whitelaw, P. Brocklehurst   +12 more
semanticscholar   +1 more source